The Notch pathway in podocytes plays a role in the development of glomerular disease

Article metrics

Abstract

Albuminuria associated with sclerosis of the glomerulus leads to a progressive decline in renal function affecting millions of people. Here we report that activation of the Notch pathway, which is critical in glomerular patterning, contributes to the development of glomerular disease. Expression of the intracellular domain of Notch1 (ICN1) was increased in glomerular epithelial cells in diabetic nephropathy and in focal segmental glomerulosclerosis. Conditional re-expression of ICN1 in vivo exclusively in podocytes caused proteinuria and glomerulosclerosis. In vitro and in vivo studies showed that ICN1 induced apoptosis of podocytes through the activation of p53. Genetic deletion of a Notch transcriptional partner (Rbpj) specifically in podocytes or pharmacological inhibition of the Notch pathway (with a γ-secretase inhibitor) protected rats with proteinuric kidney diseases. Collectively, our observations suggest that Notch activation in mature podocytes is a new mechanism in the pathogenesis of glomerular disease and thus could represent a new therapeutic target.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Expression of the Notch pathway in human and rodent models of glomerular disease.
Figure 2: Conditional de novo ICN1 expression in vivo in podocytes leads to albuminuria and severe glomerulosclerosis.
Figure 3: ICN1 expression in podocytes induces apoptosis.
Figure 4: TGF-β1 treatment increases active Notch1 in podocytes.
Figure 5: Effect of podocyte-specific Rbpj deletion on the development of diabetic nephropathy.
Figure 6: GSI XX treatment ameliorates glomerular disease in PAN-induced nephrotic syndrome.

References

  1. 1

    Hostetter, T.H. Prevention of end-stage renal disease due to type 2 diabetes. N. Engl. J. Med. 345, 910–912 (2001).

  2. 2

    USRDS. The United States Renal Data System. Am. J. Kidney Dis. 42 (Suppl. 5), 1–230 (2003).

  3. 3

    Somlo, S. & Mundel, P. Getting a foothold in nephrotic syndrome. Nat. Genet. 24, 333–335 (2000).

  4. 4

    Wolf, G., Chen, S. & Ziyadeh, F.N. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54, 1626–1634 (2005).

  5. 5

    Susztak, K., Raff, A.C., Schiffer, M. & Bottinger, E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225–233 (2006).

  6. 6

    Szabo, C., Biser, A., Benko, R., Bottinger, E. & Susztak, K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 55, 3004–3012 (2006).

  7. 7

    Isermann, B. et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat. Med. 13, 1349–1358 (2007).

  8. 8

    Mundel, P., Schwarz, K. & Reiser, J. Podocyte biology: a footstep further. Adv. Nephrol. Necker Hosp. 31, 235–241 (2001).

  9. 9

    Pagtalunan, M.E. et al. Podocyte loss and progressive glomerular injury in type II diabetes. J. Clin. Invest. 99, 342–348 (1997).

  10. 10

    Jarriault, S. et al. Signalling downstream of activated mammalian Notch. Nature 377, 355–358 (1995).

  11. 11

    Schweisguth, F. Notch signaling activity. Curr. Biol. 14, R129–R138 (2004).

  12. 12

    Ilagan, M.X. & Kopan, R. SnapShot: Notch signaling pathway. Cell 128, 1246 (2007).

  13. 13

    Cheng, H.T. et al. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development 134, 801–811 (2007).

  14. 14

    Cheng, H.T. & Kopan, R. The role of Notch signaling in specification of podocyte and proximal tubules within the developing mouse kidney. Kidney Int. 68, 1951–1952 (2005).

  15. 15

    Wang, P., Pereira, F.A., Beasley, D. & Zheng, H. Presenilins are required for the formation of comma- and S-shaped bodies during nephrogenesis. Development 130, 5019–5029 (2003).

  16. 16

    Vooijs, M. et al. Mapping the consequence of Notch1 proteolysis in vivo with NIP-CRE. Development 134, 535–544 (2007).

  17. 17

    Chen, L. & Al-Awqati, Q. Segmental expression of Notch and Hairy genes in nephrogenesis. Am. J. Physiol. Renal Physiol. 288, F939–F952 (2005).

  18. 18

    Piscione, T.D., Wu, M.Y. & Quaggin, S.E. Expression of Hairy/Enhancer of Split genes, Hes1 and Hes5, during murine nephron morphogenesis. Gene Expr. Patterns 4, 707–711 (2004).

  19. 19

    Shigehara, T. et al. Inducible podocyte-specific gene expression in transgenic mice. J. Am. Soc. Nephrol. 14, 1998–2003 (2003).

  20. 20

    Stanger, B.Z., Datar, R., Murtaugh, L.C. & Melton, D.A. Direct regulation of intestinal fate by Notch. Proc. Natl. Acad. Sci. USA 102, 12443–12448 (2005).

  21. 21

    Zweidler-McKay, P.A. et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B cell malignancies. Blood 106, 3898–3906 (2005).

  22. 22

    Bottinger, E.P. & Bitzer, M. TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 13, 2600–2610 (2002).

  23. 23

    Schiffer, M. et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest. 108, 807–816 (2001).

  24. 24

    Zavadil, J., Cermak, L., Soto-Nieves, N. & Bottinger, E.P. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 23, 1155–1165 (2004).

  25. 25

    Niimi, H., Pardali, K., Vanlandewijck, M., Heldin, C.H. & Moustakas, A. Notch signaling is necessary for epithelial growth arrest by TGF-beta. J. Cell Biol. 176, 695–707 (2007).

  26. 26

    Blokzijl, A. et al. Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J. Cell Biol. 163, 723–728 (2003).

  27. 27

    Oka, C. et al. Disruption of the mouse RBP-J kappa gene results in early embryonic death. Development 121, 3291–3301 (1995).

  28. 28

    Moeller, M.J., Sanden, S.K., Soofi, A., Wiggins, R.C. & Holzman, L.B. Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 35, 39–42 (2003).

  29. 29

    van Es, J.H. et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963 (2005).

  30. 30

    Walsh, D.W. et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim. Biophys. Acta 1782, 10–21 (2008).

  31. 31

    Ciofani, M. & Zuniga-Pflucker, J.C. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat. Immunol. 6, 881–888 (2005).

  32. 32

    Arumugam, T.V. et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat. Med. 12, 621–623 (2006).

  33. 33

    Morrissey, J. et al. Transforming growth factor-beta induces renal epithelial jagged-1 expression in fibrotic disease. J. Am. Soc. Nephrol. 13, 1499–1508 (2002).

  34. 34

    Zavadil, J. et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc. Natl. Acad. Sci. USA 98, 6686–6691 (2001).

  35. 35

    Rangarajan, A. et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20, 3427–3436 (2001).

  36. 36

    Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33, 416–421 (2003).

  37. 37

    Kim, S.B. et al. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ. 14, 982–991 (2007).

  38. 38

    Mungamuri, S.K., Yang, X., Thor, A.D. & Somasundaram, K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 66, 4715–4724 (2006).

  39. 39

    Wada, T., Pippin, J.W., Marshall, C.B., Griffin, S.V. & Shankland, S.J. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J. Am. Soc. Nephrol. 16, 2615–2625 (2005).

  40. 40

    Susztak, K. et al. Genomic strategies for diabetic nephropathy. J. Am. Soc. Nephrol. 14, S271–S278 (2003).

  41. 41

    Breyer, M.D. et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 27–45 (2005).

  42. 42

    Langham, R.G. et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45, 1572–1576 (2002).

  43. 43

    Wolfe, M.S. Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 1, 859–866 (2002).

  44. 44

    Kato, H. et al. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development 124, 4133–4141 (1997).

  45. 45

    Takemoto, M. et al. Large-scale identification of genes implicated in kidney glomerulus development and function. EMBO J. 25, 1160–1174 (2006).

  46. 46

    Mundel, P. et al. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J. Cell Biol. 139, 193–204 (1997).

Download references

Acknowledgements

We thank T. Honjo (Kyoto University) for providing the Rbpjflox mice, D. Melton (Harvard University) and B. Stanger (University of Pennsylvania) for providing the tetO-ICN1 mice, P. Mundel (Mount Sinai School of Medicine) for providing the conditionally immortalized podocyte cell line, W. Pear (University of Pennsylvania) for providing the ICN1/EGFP-MIGR retroviral construct, L. Holzman (University of Michigan) for providing the podocin-cre mice and the antibody to nephrin, and A. Biser for technical assistance. We thank the Analytical Imaging Facility at Albert Einstein College of Medicine for electron microscopy. This work was supported by 1R01DK076077 (US National Institute of Diabetes and Digestive and Kidney Diseases) and by the Carl Gottschalk Award of the American Society of Nephrology to K.S.

Author information

T.N. designed experiments, performed all cell culture and all the rat experiment and analyzed the data. B.B. helped with the in vitro studies. A.G. was responsible for breeding and phenotyping the transgenic mice. M.P.P. performed uninephrectomies on transgenic mice. J.B.K. provided the podocin-rtTA mice. D.B.T. analyzed the renal histology. K.S. designed experiments, supervised experimentation, analyzed the data, coordinated the project and wrote the manuscript.

Correspondence to Katalin Susztak.

Ethics declarations

Competing interests

The Albert Einstein College of Medicine of Yeshiva University has filed a patent application covering aspects of this research.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–6. Supplementary Tables 1–3 (PDF 951 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Niranjan, T., Bielesz, B., Gruenwald, A. et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 14, 290–298 (2008) doi:10.1038/nm1731

Download citation

Further reading